ARCT - アルコブラ （Arcturus Therapeutics Ltd.） アルコブラARCTのチャート
ARCTの企業情報
| symbol | ARCT |
|---|---|
| 会社名 | Arcturus Therapeutics Ltd （アルコブラ） |
| 分野（sector） | ― |
| 産業（industry） | ― |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Arcturus Therapeutics Ltd formerly Alcobra Ltd is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms. The Company through Arcturus Therapeutics Inc its wholly owned subsidiary based in the United States is focused on developing RNA medicines for rare infectious fibrotic and respiratory diseases with unmet medical needs including cystic fibrosis nonalcoholic steatohepatitis (NASH) and rare liver diseases as well as replicon RNA vaccines. アルコブラはイスラエルの新興バイオ医薬品会社。意欠陥多動性障害（ADHD）治療薬で、特許取得済経口薬のメタドキシン（MDX）や脆弱X症候群などの他の認知機能障害の治療薬の研究、開発、商業化に従事している。MDXは非刺激性の持続放出製剤である。本社はテルアビブ。 Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, and Cystic Fibrosis along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (209 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. |
| 本社所在地 | Azrieli Triangle Building 132 Derech Menachem Begin 39th Floor Tel-Aviv 6701101 ISR |
| 代表者氏名 | Peter C. Farrell ピーターC.ファレル |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 858-900-2660 |
| 設立年月日 | 39479 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 60人 |
| url | www.alcobra-pharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/arct |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -19.10700 |
| 終値（lastsale） | 7.52 |
| 時価総額（marketcap） | 80764800 |
| 時価総額 | 時価総額（百万ドル） 79.24800 |
| 売上高 | 売上高（百万ドル） 17.75100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 39.47100 |
| 当期純利益 | 当期純利益（百万ドル） -20.21200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Arcturus Therapeutics Ltd revenues decreased 38% to $4.8M. Net loss increased from $2.4M to $16.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and administrative increase from $2.1M to $13.3M (expense) Research and development increase of 2% to $8.2M (expense). |
ARCTのテクニカル分析
ARCTのニュース
Arcturus Therapeutics Q2 2022 Earnings Preview (NASDAQ:ARCT) 2022/08/08 21:35:05 Seeking Alpha
Arcturus Therapeutics (ARCT) is scheduled to announce Q2 earnings results on Tuesday, August 9th, after market close.The consensus EPS Estimate is -$1.88 and the consensus Revenue…
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022 2022/08/01 20:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2022 after the market close on Tuesday, August 9 and will also host a conference call and webcast at 4:30 pm
Stock Of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) Dropped By -2.46 Percent Over The Past Month, Is There Room For Downside? 2022/07/09 19:00:00 Marketing Sentinel
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 2.79. At the close of trading, the stock’s price was $19.06, to imply an increase of 0.58% or $0.11 in intraday trading. The ARCT share’s 52-week high remains $65.00, putting it -241.03% down since … Stock Of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) Dropped By -2.46 Percent Over The Past Month, Is There Room For Downside? Read More »
OMER, ARCT and MVST among after hour mover 2022/06/30 21:35:07 Seeking Alpha
Gainers:Inter & (INTR) +34%. Cytokinetics (CYTK) +6%
Arcturus gains on reports to draw takeover interest, blog report claims 2022/06/22 05:39:01 Seeking Alpha
Arcturus Therapeutics (ARCT) is said to have been approached about a takeover by CSL Limited (CSLLY), a source reportedly told Street Insider, whose account added that it is "unclear if…
Benzinga''s Top Ratings Upgrades, Downgrades For May 11, 2022 2022/05/11 14:02:45 Benzinga
Upgrades According to Roth Capital, the prior rating for Hecla Mining Co (NYSE: HL ) was changed from Neutral to Buy. In the first quarter, Hecla Mining showed an EPS of $0.01, compared to $0.06 from the year-ago quarter. The stock has a 52-week-high of $9.44 and a 52-week-low of $4.28. At the end of the last trading period, Hecla Mining closed at $4.36. According to Zelman, the prior rating for The AZEK Co Inc (NYSE: AZEK ) was changed from Hold to Buy. For the second quarter, AZEK Co had an EPS of $0.33, compared to year-ago quarter EPS of $0.25. At the moment, the stock has a 52-week-high of $50.65 and a 52-week-low of $17.00. AZEK Co closed at $17.33 at the end of the last trading period. According to Maxim Group, the prior rating for Celsius Holdings Inc (NASDAQ: CELH ) was changed from Hold to Buy. In the first quarter, Celsius Holdings showed an EPS of $0.09, compared to $0.01 from the year-ago quarter. The stock has a 52-week-high of $110.22 and a 52-week-low of $38.31. At the end of the last trading period, Celsius Holdings closed at $41.31.
Expert Ratings for Arcturus Therapeutics 2022/05/10 20:58:08 Benzinga
Within the last quarter, Arcturus Therapeutics (NASDAQ: ARCT ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 1 1 0 Last 30D 0 0 1 1 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 1 0 0 0 These 5 analysts have an average price target of $66.8 versus the current price of Arcturus Therapeutics at $16.485, implying upside. Below is a summary of how these 5 analysts rated Arcturus Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on … Full story available on Benzinga.com
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q1 2022 Results - Earnings Call Transcript 2022/05/10 03:09:06 Seeking Alpha
Arcturus Therapeutics Holdings Inc. (NASDAQ:NASDAQ:ARCT) Q1 2022 Results Earnings Conference Call May 9, 2022, 04:30 PM ET Company Participants Deepankar Roy - Senior Director, Investor…
Arcturus Therapeutics GAAP EPS of -$1.94 misses by $0.63, revenue of $5.24M misses by $1.84M 2022/05/09 20:31:42 Seeking Alpha
Arcturus Therapeutics press release (NASDAQ:ARCT): Q1 GAAP EPS of -$1.94 misses by $0.63.Revenue of $5.24M (+146.0% Y/Y) misses by $1.84M.
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress 2022/05/09 20:00:00 Wallstreet:Online
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2022, and provided corporate updates. This
Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... 2021/12/24 05:38:01 GuruFocus
Related Stocks: BIIB , IKNA , ABBV , GLPG , SIBN , LUNG , ADGI , ZBH , HCA , ERAS , SGEN , CTKB , PRLD , NTRA , ANTM , AFIB , ABCL , DCPH , AUPH , ASND , TRIL , ARCT , ALXN , ALEC ,
Arcturus Therapeutics (NASDAQ:ARCT) Shares Gap Up to $42.65 2021/12/23 15:54:45 Dakota Financial News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)s share price gapped up before the market opened on Thursday . The stock had previously closed at $42.65, but opened at $43.86. Arcturus Therapeutics shares last traded at $42.00, with a volume of 2,855 shares. ARCT has been the subject of a number of analyst reports. Barclays decreased their price []
Brokerages Expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Will Post Quarterly Sales of $12.90 Million 2021/12/22 07:50:44 Transcript Daily
Brokerages predict that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will report sales of $12.90 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Arcturus Therapeutics earnings, with the lowest sales estimate coming in at $1.50 million and the highest estimate coming in at $43.40 million. Arcturus Therapeutics reported sales []
Arcturus Therapeutics (NASDAQ:ARCT) Trading Up 8.9% 2021/12/17 17:40:41 Dakota Financial News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) was up 8.9% during trading on Friday . The stock traded as high as $46.88 and last traded at $46.83. Approximately 19,475 shares changed hands during trading, a decline of 98% from the average daily volume of 825,301 shares. The stock had previously closed at $43.00. Several research analysts have []
Brokerages Anticipate Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to Post -$1.81 Earnings Per Share 2021/12/05 15:46:42 Transcript Daily
Equities research analysts expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to report ($1.81) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Arcturus Therapeutics earnings, with estimates ranging from ($2.31) to ($0.80). Arcturus Therapeutics posted earnings of ($1.25) per share in the same quarter last year, which []